CXCR3

CXCR3

CXCR3 Informations sur la molécule

Molecule Name
C-X-C motif chemokine receptor 3
Alias de la molécule
CD182, CD183, CKR-L2, CMKAR3, GPR9, IP10-R, Mig-R, MigR
Drug Development Progress
Nombre de médicaments cliniques2
Nombre de médicaments commercialisés0
Phase de R&D la plus avancéePhase 1 Clinical
Alias de la cible
CKR-L2,G protein-coupled receptor 9,IP-10 receptor,CXCR-3,CXC-R3,CXCR3,C-X-C Motif Chemokine Receptor 3,Interferon-Inducible Protein 10 Receptor,GPR9,C-X-C Chemokine Receptor Type 3,Chemokine Receptor 3,CD183 Antigen,CMKAR3,Chemokine (C-X-C Motif) Receptor 3,Mig Receptor,IP10-R,CD182,CD183,Mig-R,MigR,Receptors, CXCR3
Contexte de la molécule
Chemokines are proteins which induce chemotaxis, promote differentiation of immune cells, and cause tissue extravasation. Given these properties, their role in anti-tumor immune response in the cancer environment is of great interest. Although immunotherapy has shown clinical benefit for some cancer patients, other patients do not respond. One of the mechanisms of resistance to checkpoint inhibitors may be chemokine signaling. The CXCL9, -10, -11/CXCR3 axis regulates immune cell migration, differentiation, and activation, leading to tumor suppression (paracrine axis). However, there are some reports that show involvements of this axis in tumor growth and metastasis (autocrine axis). Thus, a better understanding of CXCL9, -10, -11/CXCR3 axis is necessary to develop effective cancer control.

CXCR3 Liste de produits

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
OCU-110OCU-10-C-110; OGX-110; OCU-110Phase 1 ClinicalOcugenix Corp
Macular Degeneration
Details
ACT-777991ACT-777991Phase 1 ClinicalIdorsia Pharmaceuticals Ltd
Diabetes Mellitus, Type 1; Inflammation
Details